



Cystic Fibrosis and Personalized Medicine

Guest Editors:

Prof. Dr. Cornelis K. van der Ent

Department of Pulmonology
Patient Care, Utrecht University
Medical Center, Utrecht, The
Netherlands

Prof. Dr. Harry G. M. Heijerman

Department of Pulmonology,
University Medical Center
Utrecht, Utrecht, The
Netherlands

Deadline for manuscript
submissions:

closed (25 November 2021)

Message from the Guest Editors

Cystic fibrosis is the most prevalent monogenetic disease worldwide. Over 2000 different defects in the cystic fibrosis transmembrane conductance regulator (CFTR) gene have been described, not only leading to a highly diverse phenotype of the disease, but also to the development of a plethora of gene-defect specific therapies. Many new techniques and models have been developed to unravel the genotype-phenotype relationship and to develop and apply new molecules which can modify CFTR-protein function. In addition to clinical and radiological evaluation, functional measurements such as sweat testing, intestinal current measurements, and patient-derived cell models from airway and gut tissue have become available. Today, these tools are more and more helpful in driving treatment of cystic fibrosis into therotyping and real personalized medicine. For this Special Issue, we invite review articles and original studies addressing the latest developments in patient-specific drug development and evaluation of effects in patients with cystic fibrosis.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory
Medicine and Pathobiology,
Department of Surgery,
University of Toronto, 6 Queens
Pk Crescent W.F, Toronto, ON
M5S 3H2, Canada

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank: CiteScore - Q1 (Medicine (miscellaneous))

Contact Us

Journal of Personalized Medicine
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/jpm
jpm@mdpi.com
[X@JPM_MDPI](https://twitter.com/JPM_MDPI)